Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of the Safety and Efficacy of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma

NCT03711188 is registered in ClinicalTrials.gov with Immodulon Therapeutics Ltd as lead sponsor.

NCT NCT03711188
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03711188 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of the Safety and Efficacy of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma
Lead sponsor
Immodulon Therapeutics Ltd
Phase
Phase 2
Overall status
Completed
Start date
October 4, 2018
Completion date
December 2, 2021
Enrollment
16 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma